Ginkgo Bioworks Holdings, Inc. (DNA): M&A transaction — Ginkgo completes sale of Biosecurity segment to Tower Biosecurity, retains 20% stake

Ginkgo Bioworks Holdings, Inc.

On April 3, 2026, Ginkgo contributed all Biosecurity equity to Tower Biosecurity (Perimeter Systems) for ~20% of buyer's fully diluted shares.
Biosecurity will be reported as discontinued operations starting Q1 2026; pro forma results show reduced operating losses.
Pro forma 2025 net loss improved to $287.8M from $312.8M; 2024 loss improved to $507.6M from $547.0M.
The retained 20% stake will be equity-method accounted; preliminary valuation of $12.3M.
Ginkgo and Tower entered a Transition Services Agreement for temporary services.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Ginkgo Bioworks Holdings, Inc. completed a disposition involving Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (closed 2026-04-03).

Action: disposition
Counterparty: Tower Biosecurity, Inc. also known as Perimeter Systems, Inc.
Closing: 2026-04-03

Exact text from the filing

On April 3, 2026, Ginkgo Bioworks, Inc. (the "Seller"), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the "Company") completed the previously announced transaction (the "Transaction") with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the "Purchaser") pursuant to the Stock Purchase Agreement, dated as of February 26, 2026 (the "Purchase Agreement"), by and among the Seller, the Company, the Purchaser and Ginkgo Biosecurity, LLC ("Biosecurity").

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-024101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.